New Leadership at Oncolytics Biotech: Jared Kelly Takes Helm as CEO to Accelerate Pelareorep Development

San Diego, CA, June 11, 2025 (PRNewswire) -- Oncolytics Biotech appointed Jared Kelly as CEO to accelerate clinical and corporate momentum following promising trial data for its lead immunotherapy, pelareorep. Kelly, a seasoned executive behind Ambrx Biopharma’s $2B sale to J&J, is expected to drive strategic development and unlock partnerships. Pelareorep has shown >60% response rates in mPDAC patients and gained FDA Fast Track designation.

Read full article here.